Science
Mechanism of Action
Functions as a competitive inhibitor of tyrosinase and tyrosinase-related protein-1 (TRP-1), blocking the enzymatic conversion of L-tyrosine to L-DOPA and subsequent melanin synthesis without damaging melanocyte cells
Research
Clinical Evidence
High confidence0.1%
Key findings
- 01 0.3% concentration showed 84% effectiveness in melasma treatment over 24 weeks (International Journal of Dermatology)
- 02 0.1% cream demonstrated significant Melanin Index reduction in randomized split-face trial (Annals of Dermatology)
- 03 Superior tyrosinase inhibition compared to hydroquinone, arbutin, and kojic acid at 0.1-0.3% (Journal of Drugs in Dermatology)
Transparency
Dusting Analysis
Given its high potency and effective clinical range starting at 0.1%, concentrations below 0.05% are likely insufficient for meaningful brightening benefits
The Formula
Formulation
Stability
Extremely light and oxidation sensitive, requiring opaque airless packaging. Nanoemulsion or encapsulation often necessary for stability and enhanced penetration.
Synergies
- Niacinamide
- Vitamin C (in separate applications)
- Gentle AHAs
Conflicts
- Strong oxidizing agents
- Highly alkaline ingredients
- Direct UV exposure
Safety
Safety Profile
Generally well-tolerated with lower irritation potential than related compounds. Professional treatments may use up to 1.0%, while OTC formulations typically stay at 0.3% or below.
Your Skin
Skin Compatibility
Our Assessment
Verdict
A clinically-proven, next-generation brightening agent that delivers superior results with excellent tolerability across all skin types.
Related
Similar Ingredients
Finding similar ingredients…
References
Sources